title: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: Future research needs prioritization.
abstract: BACKGROUND
  A recent review evaluated the comparative effectiveness of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in patients with or at high risk for stable ischemic heart disease (IHD). The prioritization of future research needs has customarily been an informal process that is not responsive to the needs of all relevant stakeholders.
  
  
  METHODS
  As part of the Agency for Healthcare Research and Quality Effective Healthcare Program, the Duke Evidence-Based Practice Center engaged a diverse stakeholder group in 3 exercises designed to prioritize future research needs pertaining to the comparative effectiveness of ACE-I/ARB in patients with stable IHD.
  
  
  RESULTS
  Our stakeholders prioritized the following areas of research pertaining to the comparative effectiveness of ACE-I/ARB in stable IHD: (1) strategies to enhance greater evidence-based use, (2) impact of adherence on effectiveness or harms, (3) impact of comorbidities on effectiveness or harms, (4) medication impact on patient quality of life, (5) impact of demographic differences on effectiveness or harms, and (6) medication impact on incidence of new diagnoses. This project also yielded suggestions regarding potential study designs to address these future research needs.
  
  
  CONCLUSIONS
  Our stakeholders prioritized research designed to facilitate (1) tailored ACE-I/ARB treatment based on individual patient characteristics and (2) implementation of ACE-I/ARB use among patients most likely to benefit. With respect to suggested study designs, it was felt that analysis of existing data would sufficiently address many of the top-tier future research needs (FRNs).
authors.affiliation: Duke Evidence-Based Practice Center, Duke Clinical Research Institute, Durham, NC, USA. matthew.crowley@dm.duke.edu
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Crowley
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Powers
authors.forename: Evan R
authors.initials: ER
authors.lastname: Myers
authors.forename: Amanda J
authors.initials: AJ
authors.lastname: McBroom
authors.forename: Gillian D
authors.initials: GD
authors.lastname: Sanders
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D017144:Focus Groups; D005500:Follow-Up Studies; D005544:Forecasting; D006302:Health Services Research; D006801:Humans; D008297:Male; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D020380:Needs Assessment; D016032:Randomized Controlled Trials as Topic; D012106:Research / Q000458:organization & administration*; D012107:Research Design; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors